'Pharmacia' captures the focus of the new organization as an exceptionally fast-growing core pharmaceuticals business in the top tier of the industry, |
2005 was a pivotal year for Schering-Plough. We began our Turnaround phase. We achieved our goal of growing revenues and earnings. |
Looking ahead, we continue on track to build Schering- Plough into a company with the strength and breadth to deliver long-term high performance. We are moving from survive mode into thrive mode. |
Our cholesterol franchise continues to be a critical growth driver. |
Our cholesterol franchise is pivotal and continues to gain share in the United States and other major markets. |
The company's strength grows daily. It is going very nicely. |
These changes allow us to focus even more effectively on the needs of our customers in different markets, to better manage and drive growth and to build a competitive edge through innovation, speed and flexibility. |
These changes are designed to further strengthen the global finance team, which continues to play an important role in the transformation of Schering- Plough. |
Three years after beginning our Action Agenda, Schering-Plough today is delivering a solid record of performance -- growing our business and moving ahead with the turnaround phase of our six- to eight-year plan. |
We are building a special capability at Schering-Plough to respond to these and other challenges with innovation, speed and flexibility. We aspire to continue being the company delivering the most positive change of any in our peer group, as we work to deliver our Turnaround and advance our six- to eight-year Action Agenda for transformational change. |
We are building strength through transforming and energizing our key brands. |
We are very active because we recognize we have a late-stage pipeline gap. |
We continue to deliver on the promise we made when we began our turnaround in 1997 of achieving annual double digit earnings growth, ... Our results this quarter were again driven by strong growth in the U.S., where prescription sales increased 28 percent. |
We halted a downward spiral, |
We have delivered on our promise of achieving a turnaround in 1998 and double-digit earnings growth for the full year, |